Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of an Open, Single Arm, Multicenter Phase II Clinical Study on the Neoadjuvant Treatment of HER2 Expressing Myometrial Invasive Bladder Cancer With Disitamab Vedotin for Injection and Gemcitabine

NCT05723991 is registered in ClinicalTrials.gov with Chunguang yang (101937) as lead sponsor.

NCT NCT05723991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05723991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of an Open, Single Arm, Multicenter Phase II Clinical Study on the Neoadjuvant Treatment of HER2 Expressing Myometrial Invasive Bladder Cancer With Disitamab Vedotin for Injection and Gemcitabine
Lead sponsor
Chunguang yang (101937)
Phase
Phase 4
Overall status
Unknown status
Start date
September 28, 2022
Completion date
September 28, 2025
Enrollment
36 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

radical cystectomy, urothelial carcinoma